Brief: Paradigm Biopharmaceuticals Says US Ethics Approval Received For Para_Oa_012 Phase 3 Trial
15/05/2025 02:43
May 15 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX: US ETHICS APPROVAL RECEIVED FOR PARA_OA_012 PHASE 3 TRIAL Further company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt